Reviva Pharmaceuticals Holdings earnings release, May 13, 2026

Reviva Pharmaceuticals Holdings, Inc. (RVPH) · Form 8-K, Item 2.02 · Filed · SEC filing

Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights

- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 -

- FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in mid-2026 -

- Initiation of patient enrollment in RECOVER-2 registrational Phase 3 trial expected Q3 2026 -

Cupertino, Calif., May 13, 2026 – Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the first quarter ended March 31, 2026 and summarized recent business highlights.

“During the first quarter, we further refined our development strategy to strengthen the long-term value of brilaroxazine,” said Laxminarayan Bhat, Founder, President, and CEO of Reviva. “A key priority is to incorporate a new form of brilaroxazine into our clinical and regulatory pathway, which we believe has the potential to extend patent protection and commercial exclusivity of the program. We expect U.S. Food and Drug Administration (FDA) feedback on this strategy in mid-2026. In parallel, we are preparing to initiate RECOVER-2, our registrational Phase 3 trial in schizophrenia, with patient enrollment expected to begin in the third quarter of 2026. With multiple milestones ahead in 2026, we are committed to disciplined execution as we advance brilaroxazine as a differentiated treatment option for patients with schizophrenia and other neuropsychiatric disorders.”

Clinical Program and Business Highlights

Anticipated Milestones and Events

Financial Results for 2026

About Reviva

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Financial statements

Income Statement

Three Months Ended March 31, — CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Operating expensesResearch and development1,435,1354,113,537
Operating expensesGeneral and administrative1,836,8172,424,630
Operating expensesTotal operating expenses3,271,9526,538,167
Operating expensesLoss from operations-3,271,952-6,538,167
Other income (expense)Gain on remeasurement of warrant liabilities61,194
Other income (expense)Interest expense-6,653-11,620
Other income (expense)Interest income89,35486,111
Other income (expense)Other expense, net-3,390-25,145
Other income (expense)Total other income, net79,311110,540
Other income (expense)Loss before provision for income taxes-3,192,641-6,427,627
Other income (expense)Provision for income taxes3,3465,213
Other income (expense)Net loss-3,195,987-6,432,840
Net loss per share:Basic and diluted-0.46-2.61
Weighted average shares outstandingBasic and diluted7,022,9452,462,573

Balance Sheet

December 31, — CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

March 31, – 2026December 31, – 2025
AssetsCash and cash equivalents22,190,23114,438,792
AssetsPrepaid clinical trial costs819,721
AssetsPrepaid expenses and other current assets549,684664,685
AssetsTotal current assets23,559,63615,103,477
AssetsNon-current prepaid clinical trial costs819,721
AssetsTotal Assets23,559,63615,923,198
LiabilitiesShort-term debt231,274406,875
LiabilitiesAccounts payable2,085,2683,009,074
LiabilitiesAccrued clinical expenses2,675,6872,582,094
LiabilitiesAccrued compensation408,519485,899
LiabilitiesOther accrued liabilities718,407791,611
LiabilitiesTotal current liabilities6,119,1557,275,553
LiabilitiesTotal Liabilities6,119,1557,275,553
Stockholders’ EquityCommon stock, par value of $0.0001; 515,000,000 shares authorized; 12,810,377 and 5,872,865 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively12,34811,655
Stockholders’ EquityAdditional paid-in capital204,762,072192,773,942
Stockholders’ EquityAccumulated deficit-187,333,939-184,137,952
Stockholders’ EquityTotal stockholders' equity17,440,4818,647,645
Stockholders’ EquityTotal Liabilities and Stockholders’ Equity23,559,63615,923,198
Full release

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company’s plans for its brilaroxazine program including intended steps of advancing further clinical development and additional steps towards potential approval, the Company’s statements regarding its planned registrational RECOVER-2 Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia, including the expected timing of initiation of patient enrollment, statements about the Company’s planned use of a new form of brilaroxazine in its RECOVER-2 Phase 3 trial and in its future NDA submission, statements about anticipated FDA feedback, optimism about FDA alignment, and the timing thereof, statements about the Company’s strategy to strengthen the long-term value of brilaroxazine and the potential to extend patent protection and commercial exclusivity, statements about potential NDA and other regulatory submissions, the Company’s expectations regarding the anticipated clinical profile of its product candidates, including statements regarding anticipated efficacy or safety profile, and those relating to the Company’s expectations, intentions or beliefs regarding matters including product development and clinical trial plans and the timing thereof, including the anticipated timing of the availability of trial data, clinical and regulatory timelines and expenses, planned or intended additional trials or studies and the timing thereof, planned or intended regulatory submissions and the timing thereof, trial results, statements about the transition of the Company’s common stock to quotation on the OTCQB Venture Market (which is subject to additional risks compared to being listed on a national securities exchange including the Company’s ability to maintain compliance with the standards for continued quotation on the OTC Markets, together with limited liquidity, increased volatility, sporadic trading in the public market for the Company’s common stock, and that our ability to raise additional capital while trading on the OTC Markets may be adversely impacted), market opportunity, ability to raise sufficient funding, the Company’s cash position and its projected cash runway, statements about competitive position, possible or assumed future results of operations, business strategies, potential opportunities for development including partnerships, growth or expansion opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.... (truncated)be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and the Company’s other filings from time to time with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corporate Contact:

Reviva Pharmaceuticals Holdings, Inc.

Laxminarayan Bhat, PhD www.revivapharma.com

Investor Relations Contact:

LifeSci Advisors, LLC

PJ Kelleher pkelleher@lifesciadvisors.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Reviva Pharmaceuticals Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.